{
    "hands_on_practices": [
        {
            "introduction": "The first and most critical step in managing a child with acute neurological deficit is arriving at the correct diagnosis. In pediatrics, the landscape is complicated by a high frequency of \"stroke mimics\"—conditions that present like a stroke but have different underlying causes and treatments. This exercise focuses on the crucial skill of differentiating an acute ischemic stroke from one of its most common mimics, Todd paralysis, by integrating clinical course, electrophysiology, and advanced neuroimaging findings to make a timely and accurate diagnosis .",
            "id": "5192248",
            "problem": "A child presents with acute hemiparesis. You must choose the combination of temporal profile, electroencephalogram (EEG), and diffusion magnetic resonance imaging (MRI) findings that most strongly supports a diagnosis of Todd paralysis (postictal transient paresis) rather than acute ischemic stroke. Base your reasoning on the following foundational principles: neuronal energy failure from arterial occlusion causes cytotoxic edema with reduced water mobility, which increases diffusion-weighted imaging (DWI) signal and decreases the apparent diffusion coefficient (ADC) in an arterial vascular territory, and this abnormality usually persists for several days; in contrast, seizures cause transient alterations in neuronal and glial activity and ion gradients that can produce brief, non-territorial cortical changes, often with EEG evidence of epileptiform activity or postictal focal slowing, and clinical deficits that resolve within approximately $24$ to $48$ hours.\n\nWhich option best differentiates Todd paralysis from acute ischemic stroke in a pediatric patient?\n\nA. Deficit improves substantially within $12$ hours; EEG shows focal slowing with intermittent epileptiform discharges over the contralateral perirolandic cortex; DWI is normal or shows a thin, non-territorial cortical ribbon hyperintensity without a corresponding ADC decrease.\n\nB. Deficit persists beyond $24$ hours; EEG is normal or shows diffuse slowing without epileptiform activity; DWI demonstrates a wedge-shaped lesion conforming to a single arterial territory with increased DWI signal and low ADC.\n\nC. Deficit fluctuates over several weeks; EEG remains normal; DWI remains normal at serial exams.\n\nD. Deficit resolves completely within $1$ hour; EEG shows generalized $3$ Hz spike-wave discharges; DWI shows bilateral thalamic diffusion restriction with low ADC.",
            "solution": "## Problem Validation\n\n### Step 1: Extract Givens\nThe problem statement provides the following information and foundational principles:\n- **Clinical Presentation**: A child presents with acute hemiparesis.\n- **Task**: Differentiate Todd paralysis (postictal transient paresis) from acute ischemic stroke.\n- **Principle 1 (Acute Ischemic Stroke)**:\n    - Pathophysiology: Neuronal energy failure from arterial occlusion causes cytotoxic edema.\n    - Effect on Water Mobility: Cytotoxic edema leads to reduced water mobility.\n    - Imaging Findings: Reduced water mobility results in increased diffusion-weighted imaging (DWI) signal and a decreased apparent diffusion coefficient (ADC).\n    - Lesion Characteristics: The abnormality is located in an arterial vascular territory.\n    - Temporal Course: The abnormality usually persists for several days.\n- **Principle 2 (Seizures / Todd Paralysis)**:\n    - Pathophysiology: Seizures cause transient alterations in neuronal and glial activity and ion gradients.\n    - Imaging Findings: Can produce brief, non-territorial cortical changes.\n    - EEG Findings: Often associated with EEG evidence of epileptiform activity or postictal focal slowing.\n    - Clinical Course: Clinical deficits (Todd paralysis) resolve within approximately $24$ to $48$ hours.\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement is assessed against the required criteria:\n- **Scientifically Grounded**: The problem is firmly based on established principles of neurology, neuropathology, and neuroradiology. The descriptions of the pathophysiology and imaging characteristics of both acute ischemic stroke (cytotoxic edema, restricted diffusion in a vascular territory) and seizure-related changes (peri-ictal phenomena, transient deficits, EEG correlations) are factually correct and form the basis of modern clinical diagnosis.\n- **Well-Posed**: The problem is well-posed. It asks to identify a set of clinical, electrophysiological, and imaging findings that best distinguishes one diagnosis from another, based on a provided set of axioms. The task is clear, and a unique, logical solution can be derived from the given principles.\n- **Objective**: The problem is stated in precise, objective, and unbiased scientific language. It relies on foundational principles rather than subjective opinion.\n- **Completeness and Consistency**: The problem provides a self-contained and consistent set of principles sufficient to evaluate the options. There are no missing data or internal contradictions.\n- **Realism**: The clinical scenario and the described findings are realistic and commonly encountered in pediatric emergency medicine and neurology.\n\n### Step 3: Verdict and Action\nThe problem statement is valid as it is scientifically sound, well-posed, and objective. A solution can be derived by applying the provided principles.\n\n## Solution Derivation\n\nThe task is to identify the combination of findings that most strongly supports a diagnosis of Todd paralysis over acute ischemic stroke. We must use the foundational principles provided.\n\n- **For Todd Paralysis**: We expect a transient clinical deficit (resolving in approximately $24$ to $48$ hours), EEG evidence of a seizure (epileptiform discharges or postictal slowing), and MRI findings that are either normal or show transient, non-territorial changes, which notably lack the classic signature of true cytotoxic edema (i.e., may have high DWI signal but not a corresponding definite ADC decrease).\n- **For Acute Ischemic Stroke**: We expect a more persistent deficit, MRI evidence of cytotoxic edema (increased DWI signal *and* decreased ADC) in a defined arterial territory, and EEG findings that are less specific (e.g., focal slowing due to tissue injury, but not necessarily epileptiform activity).\n\nWe will now evaluate each option against these criteria.\n\n### Option-by-Option Analysis\n\n**A. Deficit improves substantially within $12$ hours; EEG shows focal slowing with intermittent epileptiform discharges over the contralateral perirolandic cortex; DWI is normal or shows a thin, non-territorial cortical ribbon hyperintensity without a corresponding ADC decrease.**\n\n- **Temporal Profile**: Improvement within $12$ hours is fully consistent with the expected resolution of Todd paralysis (within $24$ to $48$ hours).\n- **EEG**: The finding of focal slowing with epileptiform discharges over the contralateral perirolandic cortex (motor strip) is the classic electrophysiological signature of a focal seizure responsible for the hemiparesis.\n- **MRI**: The imaging description is crucial. A normal DWI, or a non-territorial cortical hyperintensity *without* a corresponding ADC decrease, precisely distinguishes a seizure-related phenomenon (like vasogenic edema or T2 shine-through) from the cytotoxic edema of an acute stroke. This pattern lacks the definitive marker of restricted diffusion.\n- **Conclusion**: This option perfectly aligns with the provided principles describing a seizure-related event (Todd paralysis) and directly contrasts with the expected findings of an acute ischemic stroke.\n- **Verdict**: **Correct**.\n\n**B. Deficit persists beyond $24$ hours; EEG is normal or shows diffuse slowing without epileptiform activity; DWI demonstrates a wedge-shaped lesion conforming to a single arterial territory with increased DWI signal and low ADC.**\n\n- **Temporal Profile**: Persistence of the deficit beyond $24$ hours argues against Todd paralysis and favors a more permanent injury like a stroke.\n- **EEG**: The absence of epileptiform activity makes a seizure less likely. Diffuse slowing is a non-specific finding.\n- **MRI**: A wedge-shaped, arterial territory lesion with increased DWI signal and low ADC is the textbook definition of an acute ischemic stroke, indicating irreversible cytotoxic edema.\n- **Conclusion**: Every element of this option points directly to a diagnosis of acute ischemic stroke, not Todd paralysis.\n- **Verdict**: **Incorrect**.\n\n**C. Deficit fluctuates over several weeks; EEG remains normal; DWI remains normal at serial exams.**\n\n- **Temporal Profile**: A deficit that fluctuates over weeks is not characteristic of Todd paralysis, which is a monophasic event resolving in hours to days. It is also not typical for a single acute stroke. This pattern suggests other pathologies (e.g., metabolic disorders, demyelination, or perhaps recurrent transient ischemic attacks).\n- **EEG**: A persistently normal EEG makes a seizure-related etiology highly unlikely.\n- **MRI**: A normal DWI rules out a significant ischemic stroke but does not, in combination with the other features, point to Todd paralysis.\n- **Conclusion**: This clinical picture is inconsistent with the typical presentation of either Todd paralysis or a single acute ischemic stroke.\n- **Verdict**: **Incorrect**.\n\n**D. Deficit resolves completely within $1$ hour; EEG shows generalized $3$ Hz spike-wave discharges; DWI shows bilateral thalamic diffusion restriction with low ADC.**\n\n- **Temporal Profile**: Rapid resolution within $1$ hour is consistent with a postictal state.\n- **EEG**: Generalized $3$ Hz spike-wave discharges are the hallmark of typical absence seizures. Absence seizures cause episodes of impaired awareness (staring spells), not focal motor deficits like hemiparesis. Therefore, the EEG finding is incongruent with the clinical sign of hemiparesis.\n- **MRI**: Bilateral thalamic diffusion restriction (high DWI, low ADC) indicates severe, often ischemic, injury to a specific deep brain structure (e.g., from an artery of Percheron occlusion). This is a definitive sign of stroke, not a transient postictal change.\n- **Conclusion**: This option contains fundamental inconsistencies. The EEG pattern does not match the clinical deficit, and the MRI findings indicate a severe, bilateral stroke, contradicting a diagnosis of benign Todd paralysis.\n- **Verdict**: **Incorrect**.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Once a diagnosis is established, the next step involves complex therapeutic decision-making, which often requires weighing competing risks. This is particularly true in cerebral venous sinus thrombosis (CVST), where the condition itself can cause intracranial hemorrhage. This practice problem challenges you to apply first principles of pathophysiology and evidence-based guidelines to justify the seemingly paradoxical decision to start anticoagulation in a patient who is already bleeding, a cornerstone of modern CVST management .",
            "id": "5192324",
            "problem": "A child aged $8$ years presents with headache, emesis, and focal seizures following $10$ days of acute otitis media complicated by mastoiditis. Magnetic Resonance Imaging (MRI) and Magnetic Resonance Venography (MRV) demonstrate Cerebral Venous Sinus Thrombosis (CVST) involving the transverse and sigmoid sinuses, with a small cortical Intracranial Hemorrhage (ICH) consistent with hemorrhagic transformation of a venous infarct. Platelet count and fibrinogen are within reference ranges, and prothrombin time and activated partial thromboplastin time are not prolonged. There is no evidence of a large parenchymal hematoma, mass effect, or uncontrolled hypertension. The multidisciplinary team debates whether to initiate Low Molecular Weight Heparin (LMWH).\n\nUsing foundational principles of hemostasis and venous thrombosis, and integrating high-quality pediatric evidence and consensus guideline recommendations, which option best justifies initiating LMWH in this scenario even in the presence of a small ICH?\n\nA. Initiate LMWH because, by binding antithrombin and preferentially inhibiting factor $X_a$ over $II_a$, it reduces thrombin generation and prevents thrombus propagation; in pediatric CVST with small ICH, cohort and registry data demonstrate lower rates of thrombus extension and improved recanalization without a clinically significant increase in hemorrhage expansion, and expert guidelines from the American Heart Association/American Stroke Association (AHA/ASA) and the American College of Chest Physicians (CHEST) recommend anticoagulation unless there is large hematoma or impending herniation.\n\nB. Withhold anticoagulation because any ICH is an absolute contraindication to heparin, and pediatric data show a high risk of hemorrhage expansion under LMWH that outweighs prevention of thrombus propagation.\n\nC. Favor endovascular thrombolysis over LMWH because fibrinolysis rapidly dissolves clot and is supported by randomized pediatric trials demonstrating superior neurological outcomes and a lower risk of bleeding compared to anticoagulation in CVST with ICH.\n\nD. Give platelet transfusions and avoid LMWH because LMWH primarily impairs platelet function, which would amplify bleeding risk in venous infarction; platelets will improve hemostasis and permit spontaneous recanalization.\n\nE. Prefer unfractionated heparin rather than LMWH because unfractionated heparin has proven superior pediatric CVST outcomes and is mechanistically preferable in ICH due to stronger direct thrombin ($II_a$) inhibition, making LMWH inappropriate when hemorrhage is present.",
            "solution": "The problem statement is evaluated for validity prior to attempting a solution.\n\n### Step 1: Extract Givens\n- **Patient**: A child aged $8$ years.\n- **Presentation**: Headache, emesis, and focal seizures.\n- **Antecedent History**: $10$ days of acute otitis media complicated by mastoiditis.\n- **Imaging Findings (MRI/MRV)**: Cerebral Venous Sinus Thrombosis (CVST) involving the transverse and sigmoid sinuses. A small cortical Intracranial Hemorrhage (ICH) consistent with hemorrhagic transformation of a venous infarct.\n- **Laboratory Findings**: Platelet count and fibrinogen are within reference ranges. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) are not prolonged.\n- **Additional Clinical Findings**: No evidence of a large parenchymal hematoma, mass effect, or uncontrolled hypertension.\n- **Clinical Question**: The multidisciplinary team is debating the initiation of Low Molecular Weight Heparin (LMWH).\n- **Task**: To select the option that best justifies initiating LMWH in this scenario, based on principles of hemostasis, pediatric evidence, and guidelines.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientifically Grounded**: The problem describes a classic and well-documented clinical scenario. Septic CVST is a known complication of deep head and neck infections like mastoiditis. The pathophysiology described—venous sinus occlusion leading to a venous infarct with secondary hemorrhagic transformation—is a core concept in neurology and hematology. The proposed intervention (anticoagulation) and the clinical dilemma (balancing thrombosis risk vs. bleeding risk) are central to the management of this condition. The problem is scientifically and factually sound.\n2.  **Well-Posed**: The problem is clearly stated. It provides a specific clinical vignette with sufficient detail to allow for a reasoned decision. The question asks for the best justification among the given options, which requires an analysis of pathophysiology, pharmacology, and clinical evidence. A unique, best answer can be determined by referencing established medical science and clinical guidelines.\n3.  **Objective**: The problem statement uses precise, objective clinical terminology. The findings (e.g., \"small cortical ICH,\" \"no mass effect,\" specific lab results) are objective and free of subjective or ambiguous language.\n\n### Step 3: Verdict and Action\nThe problem statement is valid. It is a scientifically grounded, well-posed, and objective clinical reasoning problem. I will now proceed to derive the solution and evaluate each option.\n\n### Derivation\nThe core of this problem lies in the risk-benefit analysis of anticoagulation for Cerebral Venous Sinus Thrombosis (CVST) in the presence of a secondary Intracranial Hemorrhage (ICH).\n\n**Pathophysiological Principles**:\n1.  The primary pathology is the thrombus in the venous sinus. This thrombus obstructs venous outflow from the brain.\n2.  The obstruction elevates upstream venous and capillary pressure. This can lead to two main consequences:\n    a.  **Venous Infarction**: Ischemic brain injury due to poor venous drainage and subsequent edema.\n    b.  **Hemorrhage**: Rupture of distended, high-pressure venules and capillaries, leading to parenchymal hemorrhage. This is often termed hemorrhagic transformation of the venous infarct.\n3.  The fundamental therapeutic goal is to address the underlying thrombus. The logic is that by halting the propagation of the thrombus, anticoagulation allows for endogenous fibrinolysis and recanalization of the sinus. This, in turn, lowers the venous pressure, treating the root cause of both the infarct and the hemorrhage. Therefore, treating the thrombosis is paramount to preventing further hemorrhagic and ischemic injury.\n\n**Pharmacological Principles (LMWH)**:\n1.  Low Molecular Weight Heparin (LMWH) is an anticoagulant. Its mechanism of action involves binding to and potentiating the activity of antithrombin (AT), a natural inhibitor of coagulation proteases.\n2.  The LMWH-AT complex has a high affinity for inhibiting Factor $X_a$. Inhibition of Factor $X_a$ blocks the conversion of prothrombin (Factor $II$) to thrombin (Factor $II_a$). This drastically reduces thrombin generation, which is the central enzyme in the coagulation cascade responsible for converting fibrinogen to fibrin, the structural basis of a clot.\n3.  Compared to Unfractionated Heparin (UFH), LMWH has a higher ratio of anti-$X_a$ to anti-$II_a$ activity.\n4.  By preventing new thrombin generation, LMWH effectively stops the existing thrombus from growing (propagation) and prevents the formation of new thrombi, but it does not actively dissolve the existing clot (that is the function of fibrinolysis).\n\n**Clinical Evidence and Guidelines**:\n1.  The presence of ICH in the context of CVST is common and is not considered an absolute contraindication to anticoagulation.\n2.  Clinical guidelines from major bodies such as the American Heart Association/American Stroke Association (AHA/ASA) and the American College of Chest Physicians (CHEST) recommend anticoagulation with heparin (either LMWH or UFH) for pediatric and adult CVST, even in the setting of secondary hemorrhage.\n3.  The primary contraindications to initiating anticoagulation are a very large hematoma that is causing significant mass effect, impending brain herniation, or other conditions posing an unacceptably high risk of bleeding (e.g., severe thrombocytopenia, uncontrolled systemic hypertension), none of which are present in this case.\n4.  Observational data, including cohort studies and international registries in pediatrics, have shown that initiation of anticoagulation in this scenario is associated with favorable outcomes, including lower rates of thrombus propagation, higher rates of sinus recanalization, and improved neurological outcomes, without a statistically significant increase in the rate of major hemorrhage expansion.\n\n**Conclusion of Derivation**: In this specific case—a child with septic CVST, a small associated cortical ICH, and no other major contraindications—the balance of risks and benefits strongly favors the initiation of anticoagulation with LMWH. The aim is to halt thrombus propagation, which is the driving force behind the ongoing brain injury (both ischemic and hemorrhagic).\n\n### Option-by-Option Analysis\n\n**A. Initiate LMWH because, by binding antithrombin and preferentially inhibiting factor $X_a$ over $II_a$, it reduces thrombin generation and prevents thrombus propagation; in pediatric CVST with small ICH, cohort and registry data demonstrate lower rates of thrombus extension and improved recanalization without a clinically significant increase in hemorrhage expansion, and expert guidelines from the American Heart Association/American Stroke Association (AHA/ASA) and the American College of Chest Physicians (CHEST) recommend anticoagulation unless there is large hematoma or impending herniation.**\nThis option correctly describes the mechanism of LMWH (potentiation of antithrombin, preferential anti-$X_a$ activity, reduction of thrombin generation, prevention of propagation). It accurately summarizes the pediatric clinical evidence (favorable risk-benefit profile in CVST with small ICH, supported by registry/cohort data). It correctly cites the recommendations of major professional guidelines (AHA/ASA, CHEST), which support anticoagulation and define the key contraindications (large hematoma, herniation), which are absent here. The entire statement is a comprehensive and accurate justification for the indicated therapy.\n**Verdict: Correct**\n\n**B. Withhold anticoagulation because any ICH is an absolute contraindication to heparin, and pediatric data show a high risk of hemorrhage expansion under LMWH that outweighs prevention of thrombus propagation.**\nThis statement is factually incorrect. ICH secondary to venous infarction is a relative, not absolute, contraindication for anticoagulation. Furthermore, the available pediatric evidence suggests that the benefit of preventing thrombus propagation outweighs the risk of hemorrhage expansion for small, non-space-occupying bleeds. This option misrepresents both the standard of care and the supporting evidence.\n**Verdict: Incorrect**\n\n**C. Favor endovascular thrombolysis over LMWH because fibrinolysis rapidly dissolves clot and is supported by randomized pediatric trials demonstrating superior neurological outcomes and a lower risk of bleeding compared to anticoagulation in CVST with ICH.**\nThis option is incorrect on several points. First, endovascular therapy (including chemical thrombolysis) is considered a second-line or rescue therapy for CVST, reserved for patients with severe presentations or clinical deterioration despite adequate anticoagulation. It is not the first-line treatment. Second, there are no large-scale randomized pediatric trials supporting its superiority over anticoagulation; the evidence is limited. Third, and most critically, thrombolysis carries a *higher*, not lower, risk of bleeding complications compared to standard anticoagulation.\n**Verdict: Incorrect**\n\n**D. Give platelet transfusions and avoid LMWH because LMWH primarily impairs platelet function, which would amplify bleeding risk in venous infarction; platelets will improve hemostasis and permit spontaneous recanalization.**\nThis statement is mechanistically and clinically flawed. LMWH's primary mechanism is on the coagulation cascade via antithrombin, not platelet function. While Heparin-Induced Thrombocytopenia (HIT) is a rare adverse effect involving platelets, it is not the primary mechanism of action. The patient's platelet count is normal, so a platelet transfusion is not indicated and could be prothrombotic. Promoting hemostasis by adding platelets without addressing the thrombotic process is illogical and not the standard of care.\n**Verdict: Incorrect**\n\n**E. Prefer unfractionated heparin rather than LMWH because unfractionated heparin has proven superior pediatric CVST outcomes and is mechanistically preferable in ICH due to stronger direct thrombin ($II_a$) inhibition, making LMWH inappropriate when hemorrhage is present.**\nThis option contains multiple falsehoods. There is no evidence that UFH has \"proven superior\" outcomes compared to LMWH in pediatric CVST; LMWH is often preferred for its stable pharmacokinetics and ease of use. The claim that stronger $II_a$ inhibition is \"mechanistically preferable\" in the setting of ICH is not a recognized principle; a more potent anticoagulant effect could logically increase bleeding risk. While the short half-life of UFH is an advantage in some high-risk situations, the statement incorrectly frames this as a mechanistic preference and wrongly concludes that LMWH is \"inappropriate.\" Both UFH and LMWH are considered acceptable options.\n**Verdict: Incorrect**",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Following the critical decisions of diagnosis and treatment selection comes the essential task of execution, where precision is paramount. For time-sensitive, high-risk therapies like intravenous thrombolysis, accurate dose calculation is a non-negotiable component of patient safety. This final exercise provides hands-on practice in the multi-step calculation of a weight-based alteplase regimen, from the total dose to the bolus and infusion rate, ensuring you can confidently and correctly administer this life-altering therapy .",
            "id": "5192239",
            "problem": "A $10$-year-old child with confirmed acute arterial ischemic stroke is deemed eligible for intravenous recombinant tissue plasminogen activator (tPA) therapy with alteplase under a pediatric stroke protocol. The child weighs $35$ kg. The protocol specifies a total mass-normalized dose of $0.9$ mg/kg, administered as an initial $10\\%$ intravenous bolus followed by a continuous infusion of the remaining $90\\%$ over $60$ minutes. Clinicians sometimes apply an adult maximum total dose cap of $90$ mg; assume this cap applies if the calculated weight-based total would exceed it.\n\nStarting only from the following fundamental bases: (i) the definition of weight-based dosing as total dose equals mass-normalized dose multiplied by body mass, (ii) the definition of a proportion as a fraction of a whole, and (iii) the definition of infusion rate as dose delivered per unit time, derive the absolute total dose, the absolute bolus dose, the absolute infusion dose, and the infusion rate.\n\nState any cap check clearly and apply it if limiting. Round your results to three significant figures. Express doses in mg and the rate in mg/min. Present your final answer as a single row matrix in the order: total dose (mg), bolus dose (mg), infusion dose (mg), infusion rate (mg/min). Do not include units inside the final boxed answer.",
            "solution": "The problem is evaluated for validity before proceeding to a solution.\n\n### Step 1: Extract Givens\n- Child's body mass, $m = 35$ kg.\n- Total mass-normalized dose of alteplase, $d_{norm} = 0.9$ mg/kg.\n- Proportion of total dose for initial intravenous bolus, $P_{bolus} = 10\\%$.\n- Proportion of total dose for continuous infusion, $P_{infusion} = 90\\%$.\n- Duration of continuous infusion, $T_{infusion} = 60$ minutes.\n- Adult maximum total dose cap, $D_{max} = 90$ mg.\n- Assumption: The cap applies if the calculated weight-based total dose exceeds it.\n- Fundamental bases for derivation:\n    - (i) Definition of weight-based dosing: total dose equals mass-normalized dose multiplied by body mass.\n    - (ii) Definition of a proportion as a fraction of a whole.\n    - (iii) Definition of infusion rate as dose delivered per unit time.\n- Output requirements:\n    - Derive: absolute total dose, absolute bolus dose, absolute infusion dose, and the infusion rate.\n    - Round final results to three significant figures.\n    - Express doses in mg and the rate in mg/min.\n    - Present the final answer as a single row matrix.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded. The specified dose of alteplase ($0.9$ mg/kg), administration protocol ($10\\%$ bolus, $90\\%$ infusion over $60$ minutes), and maximum dose cap ($90$ mg) are consistent with established clinical guidelines for thrombolytic therapy in acute ischemic stroke (e.g., American Heart Association/American Stroke Association guidelines). The provided values for the child's weight and the dosage are physically and medically realistic. The problem is well-posed, objective, and self-contained, with all necessary information provided for a unique solution. It does not violate any of the invalidity criteria.\n\n### Step 3: Verdict and Action\nThe problem is valid. A formal solution will be derived.\n\n### Derivation\nLet $m$ be the body mass of the child, $d_{norm}$ be the mass-normalized dose, and $D_{max}$ be the maximum total dose cap.\nThe given values are:\n- $m = 35$ kg\n- $d_{norm} = 0.9$ mg/kg\n- $D_{max} = 90$ mg\n\n**1. Calculate the initial weight-based total dose ($D_{calc}$)**\nBased on the provided definition (i), the total dose is the product of the mass-normalized dose and the body mass.\n$$D_{calc} = d_{norm} \\times m$$\nSubstituting the given values:\n$$D_{calc} = (0.9 \\text{ mg/kg}) \\times (35 \\text{ kg}) = 31.5 \\text{ mg}$$\n\n**2. Apply the maximum dose cap**\nThe problem requires checking if the calculated dose $D_{calc}$ exceeds the maximum cap $D_{max}$.\nThe condition to check is $D_{calc} > D_{max}$.\n$$31.5 \\text{ mg} > 90 \\text{ mg}$$\nThis statement is false. Therefore, the dose cap does not apply, and the actual total dose to be administered, $D_{total}$, is equal to the calculated dose.\n$$D_{total} = D_{calc} = 31.5 \\text{ mg}$$\n\n**3. Calculate the absolute bolus dose ($D_{bolus}$)**\nThe bolus dose is a proportion, $P_{bolus} = 10\\% = 0.10$, of the total dose. Based on the provided definition (ii):\n$$D_{bolus} = P_{bolus} \\times D_{total}$$\n$$D_{bolus} = 0.10 \\times 31.5 \\text{ mg} = 3.15 \\text{ mg}$$\n\n**4. Calculate the absolute infusion dose ($D_{infusion}$)**\nThe infusion dose is the remaining proportion, $P_{infusion} = 90\\% = 0.90$, of the total dose.\n$$D_{infusion} = P_{infusion} \\times D_{total}$$\n$$D_{infusion} = 0.90 \\times 31.5 \\text{ mg} = 28.35 \\text{ mg}$$\nA consistency check confirms that the sum of the bolus and infusion doses equals the total dose: $D_{bolus} + D_{infusion} = 3.15 \\text{ mg} + 28.35 \\text{ mg} = 31.5 \\text{ mg} = D_{total}$.\n\n**5. Calculate the infusion rate ($R_{infusion}$)**\nThe infusion is administered over a duration $T_{infusion} = 60$ min. Based on the provided definition (iii), the infusion rate is the dose delivered per unit time.\n$$R_{infusion} = \\frac{D_{infusion}}{T_{infusion}}$$\n$$R_{infusion} = \\frac{28.35 \\text{ mg}}{60 \\text{ min}} = 0.4725 \\text{ mg/min}$$\n\n**6. Rounding to Three Significant Figures**\nThe problem requires that the final results be rounded to three significant figures.\n- Total Dose: $D_{total} = 31.5$ mg. This value already has three significant figures.\n- Bolus Dose: $D_{bolus} = 3.15$ mg. This value already has three significant figures.\n- Infusion Dose: $D_{infusion} = 28.35$ mg. Rounding to three significant figures gives $28.4$ mg.\n- Infusion Rate: $R_{infusion} = 0.4725$ mg/min. Rounding to three significant figures gives $0.473$ mg/min.\n\nThe required values, expressed in the correct units and rounded to three significant figures, are:\n- Total Dose: $31.5$ mg\n- Bolus Dose: $3.15$ mg\n- Infusion Dose: $28.4$ mg\n- Infusion Rate: $0.473$ mg/min\n\nThese results are to be presented in a single row matrix in the specified order.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n31.5 & 3.15 & 28.4 & 0.473\n\\end{pmatrix}\n}\n$$"
        }
    ]
}